Frost & Sullivan Independent Equity Research

Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2.

Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Company: Oramed Pharmaceuticals Inc.        

Sector: Pharmaceuticals

Report type: Update for the quarterly period ending 28.2.18

Published on: 26 April, 2018

Oramed research articles: